All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @itsamyosage on TikTok · 106s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @itsamyosage's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Six weeks on semaglutide let's talk results and let's talk side effects. All right results in six weeks
  2. 0:06I have lost 13 pounds I
  3. 0:10I'm averaging about two pounds a week or so
  4. 0:14Which is great, which is exactly where my doctor would want me to be not necessarily
  5. 0:20Doesn't want me to be losing anything more than that in terms of side effects. Let's start with the crappy side effects
  6. 0:28So first let's talk about nausea. I have had some nausea the only time I have nausea is when I have not ate enough
  7. 0:35So if I'm starting to feel sick to my stomach that is my cue girl you need to eat
  8. 0:42Second side effect, you know, I hate is really the worst one and the worst one for me has been constipation
  9. 0:49Rough one out there. I'm pumping myself full of fiber start taking fiber supplements. So when I do that
  10. 0:55It's not nearly as bad
  11. 0:58good side effects guys
  12. 1:00the food noise is completely vanished I
  13. 1:05I feel like I have control over my nutrition for the first time in
  14. 1:11Like my entire adult life and so it's very
  15. 1:17I'm also noticing it just that I'm really focusing on my healthy habits not necessarily just losing weight for the first
  16. 1:24losing weight. I want to continue with healthy habits of
  17. 1:29managing my nutrition moving my body
  18. 1:32prioritizing my physical health my mental health after this is done. So I've found a lot of
  19. 1:39confidence in myself to be able to do that and so that's why I'm at six weeks in and I'm feeling fantastic

@itsamyosage's six-week semaglutide update, fact-checked

itsamyosage

TikTok creator

270.2K viewsWatch on TikTok

Quick answer

The creator is six weeks into semaglutide therapy and reporting 13 pounds of weight loss alongside typical GI side effects including nausea and constipation, both of which are consistent with the drug's known pharmacological profile during early titration. Her self-management strategies, specifically fiber supplementation for constipation, align with standard clinical guidance. Her reported disappearance of food cravings reflects the documented central appetite-suppressing mechanism of GLP-1 receptor agonists acting on hypothalamic reward pathways.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @itsamyosage's six-week semaglutide update, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@itsamyosage's six-week semaglutide update, fact-checked" from itsamyosage. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is six weeks into semaglutide therapy and reporting 13 pounds of weight loss alongside typical GI side effects including nausea and constipation, both of which are consistent with the drug's known pharmacological profile during early titration.

The reason this review is not generic is the source wording and the canonical claim label "glp1 six week semaglutide update glp1forweightloss semaglutid." In this clip, the useful excerpt is: "Six weeks on semaglutide let's talk results and let's talk side effects." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Nausea occurs in roughly 44% of semaglutide users per STEP trial data and is caused by slowed gastric emptying and central GLP-1 receptor activity, not just undereating.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is six weeks into semaglutide therapy and reporting 13 pounds of weight loss alongside typical GI side effects including nausea and constipation, both of which are consistent with the drug's known pharmacological profile during early titration.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is six weeks into semaglutide therapy and reporting 13 pounds of weight loss alongside typical GI side effects including nausea and constipation, both of which are consistent with the drug's known pharmacological profile during early titration. Her self-management strategies, specifically fiber supplementation for constipation, align with standard clinical guidance. Her reported disappearance of food cravings reflects the documented central appetite-suppressing mechanism of GLP-1 receptor agonists acting on hypothalamic reward pathways.
  • STEP 1 trial data (Wilding et al., 2021, NEJM) showed average 14.9% body weight loss over 68 weeks; early-phase results often run faster before plateauing.
  • Nausea occurs in roughly 44% of semaglutide users per STEP trial data and is caused by slowed gastric emptying and central GLP-1 receptor activity, not just undereating.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • STEP 1 trial data (Wilding et al., 2021, NEJM) showed average 14.9% body weight loss over 68 weeks; early-phase results often run faster before plateauing.
  • Nausea occurs in roughly 44% of semaglutide users per STEP trial data and is caused by slowed gastric emptying and central GLP-1 receptor activity, not just undereating.
  • Constipation affects approximately 24% of semaglutide users; fiber supplementation is a clinically supported first-line management strategy.
  • Food noise reduction is a pharmacological effect documented in clinical trials, not a placebo or motivation shift. Blundell et al. (2017) confirmed significant appetite and craving reductions versus placebo.
  • STEP 5 data (Garvey et al., 2022, Nature Medicine) showed meaningful weight regain after semaglutide discontinuation, making habit formation during treatment clinically important, not just motivationally appealing.
  • Semaglutide requires a prescription and a titration schedule designed to reduce side effects; persistent or severe GI symptoms should be discussed with a prescribing provider, not self-managed by eating more.
  • Individual results at six weeks depend on starting weight, dose level, dietary habits, activity, and metabolic factors; a single creator's result is not a reliable benchmark.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @itsamyosage actually say?

At six weeks on semaglutide, the creator reported losing 13 pounds, which she frames as averaging "about two pounds a week or so." She described two notable side effects: nausea that she says only appears when she hasn't eaten enough, and constipation she's managing with fiber supplements. On the positive side, she said "the food noise is completely vanished" and that she feels control over her nutrition "for the first time in like my entire adult life." She also emphasized a shift in mindset toward sustainable habits rather than just scale outcomes.

That's actually a more balanced take than most GLP-1 content on TikTok. She didn't promise a number, didn't recommend a dose, and acknowledged the rough parts. Credit where it's due.

Does the science back this up?

Mostly, yes. The 2021 STEP 1 trial (Wilding et al., New England Journal of Medicine) showed average weight loss of about 14.9% of body weight over 68 weeks in people on 2.4mg semaglutide weekly. Early weight loss in the first several weeks tends to be faster before the rate stabilizes, so 13 pounds at six weeks is plausible depending on starting weight, though it sits on the higher end of typical early-phase results.

The side effect profile she describes is well-documented. Nausea occurs in roughly 44% of semaglutide users according to STEP trial data, and constipation affects around 24%. Her observation that nausea correlates with undereating is consistent with clinical experience: semaglutide slows gastric emptying, and an empty stomach can amplify that effect. Fiber supplementation for constipation is a standard first-line recommendation, so she's doing the right thing there.

The "food noise" reduction she describes reflects the drug's mechanism. Semaglutide acts on GLP-1 receptors in the hypothalamus and brainstem, reducing appetite signaling and reward-driven eating behavior. Research by Blundell et al. (2017, Diabetes, Obesity and Metabolism) confirmed significant reductions in appetite and food cravings in semaglutide users compared to placebo.

What did they get wrong (or right)?

The creator got the core side effect picture right, and her fiber-for-constipation advice is sound. Her framing of nausea as a hunger cue is partially correct but worth nuancing: nausea on semaglutide isn't always about undereating. It can occur regardless of meal timing, especially during dose escalation phases. Treating every episode of nausea as a signal to eat more could lead someone to override their appetite suppression in counterproductive ways.

Her 2-pounds-per-week average is real, but she presents it as a steady, reliable rate. In practice, GLP-1 weight loss is not linear. Most people experience faster initial loss followed by plateau periods. The 2022 STEP 5 trial (Garvey et al., Nature Medicine) showed meaningful weight regain when semaglutide was discontinued, a reality worth knowing upfront.

What she got right: the psychological dimension. Her focus on habit formation and mental health alongside weight loss reflects what the clinical literature actually supports for long-term outcomes. That framing is more honest than most weight-loss content online.

What should you actually know?

Thirteen pounds in six weeks is attention-grabbing, but context matters significantly. Individual results depend on starting weight, dose level, diet, activity, and metabolic factors. The STEP trials showed that roughly 86% of participants lost at least 5% of body weight, but individual variation is wide.

Semaglutide is a prescription medication with a structured dose escalation protocol designed to minimize side effects. The nausea and constipation she described are common enough that clinical guidelines recommend slow titration specifically to reduce them. If you're experiencing persistent or severe GI symptoms, that's a conversation for your prescribing provider, not a reason to eat more or push through.

The "food noise" effect is real and clinically documented, but it does not mean the medication does the work alone. Studies consistently show that people who pair GLP-1 therapy with behavioral support maintain better long-term outcomes. Her instinct to focus on habits is not just feel-good framing; it's backed by evidence.

  • Side effects are real and common: nausea affects roughly 44%, constipation roughly 24% of users in clinical trials.
  • Early weight loss may feel faster than the long-term average, which is expected during initial dose escalation.
  • Food noise reduction is a documented pharmacological effect, not just a mindset shift.
  • Weight often returns after stopping semaglutide without sustained lifestyle support, per STEP extension data.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

itsamyosage · TikTok creator

270.2K views on this video

Six Week #semaglutide update! #glp1forweightloss #semaglutideweightloss @Ivím Health

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about step 1 trial data (wilding et al., 2021, nejm) showed?

STEP 1 trial data (Wilding et al., 2021, NEJM) showed average 14.9% body weight loss over 68 weeks; early-phase results often run faster before plateauing.

What does the video say about nausea occurs in roughly 44% of semaglutide users per step?

Nausea occurs in roughly 44% of semaglutide users per STEP trial data and is caused by slowed gastric emptying and central GLP-1 receptor activity, not just undereating.

What does the video say about constipation affects approximately 24% of semaglutide users; fiber supplementation?

Constipation affects approximately 24% of semaglutide users; fiber supplementation is a clinically supported first-line management strategy.

What does the video say about food noise reduction?

Food noise reduction is a pharmacological effect documented in clinical trials, not a placebo or motivation shift. Blundell et al. (2017) confirmed significant appetite and craving reductions versus placebo.

What does the video say about step 5 data (garvey et al., 2022, nature medicine) showed?

STEP 5 data (Garvey et al., 2022, Nature Medicine) showed meaningful weight regain after semaglutide discontinuation, making habit formation during treatment clinically important, not just motivationally appealing.

What does the video say about semaglutide requires a prescription?

Semaglutide requires a prescription and a titration schedule designed to reduce side effects; persistent or severe GI symptoms should be discussed with a prescribing provider, not self-managed by eating more.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by itsamyosage, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.